EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Safety and Pharmacokinetics of Intravenous and Oral Fosmanogepix, a First-in-Class Antifungal Agent, in Healthy Volunteers

Michael R Hodges, Eric Ople, Pamela Wedel, Karen J Shaw, Abhijeet Jakate, William G Kramer, Sjoerd van Marle, Ewoud-Jan van Hoogdalem, Margaret Tawadrous iD

Antimicrobial Agents and Chemotherapy · 18.04.2023 · 67 (4)

DOI: 10.1128/aac.01623-22 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 18.04.2023. Verfasst von Michael R Hodges und 8 weiteren Autor:innen. Beteiligte Einrichtung: Amplyx Pharmaceuticals, Inc., San Diego, California, USA. Hauptthemen laut MEDLINE: Antifungal Agents, Invasive Fungal Infections. Die Arbeit wurde bisher 57-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Amplyx.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fosmanogepix (FMGX, APX001), a first-in-class, intravenous (i.v.) and oral (p.o.) antifungal prodrug candidate is currently in clinical development for the treatment of invasive fungal infections. Manogepix (MGX, APX001A), the active moiety of FMGX, interferes with cell wall synthesis by targeting fungal glycosylphosphatidylinositol-anchored cell wall transfer protein 1, thereby causing loss of cell viability.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antifungal AgentsInvasive Fungal InfectionsAdultHumansHealthy VolunteersBiological AvailabilityArea Under CurveDouble-Blind MethodDose-Response Relationship, DrugAminopyridinesIsoxazoles

Stichwörter der Autor:innen

APX001APX001AGwt1 inhibitorclinical trialsfosmanogepixintravenousmanogepixmultiple ascending dosesorally bioavailablephase 1single ascending dose

Substanzen

Antifungal AgentsAPX001AAminopyridinesIsoxazoles

Autor:innen und Institutionen

  • Amplyx Pharmaceuticals, Inc., San Diego, California, USA.
  • Hearts Consulting Group, LLC, Poway, California, USA.
  • Pfizer Inc., Groton, Connecticut, USA.
  • Kramer Consulting, LLC, North Potomac, Maryland, USA.
  • ICON, Groningen, the Netherlands.

ORCID-Profile: Margaret Tawadrous

Förderung

  • Amplyx

Zitieren

APA

Hodges, M. R., Ople, E., Wedel, P., Shaw, K. J., Jakate, A., Kramer, W. G., Marle, S. V., van Hoogdalem, E. J., & Tawadrous, M. (2023). Safety and Pharmacokinetics of Intravenous and Oral Fosmanogepix, a First-in-Class Antifungal Agent, in Healthy Volunteers. Antimicrobial Agents and Chemotherapy, 67(4). https://doi.org/10.1128/aac.01623-22

Vancouver

Hodges MR, Ople E, Wedel P, Shaw KJ, Jakate A, Kramer WG, et al. Safety and Pharmacokinetics of Intravenous and Oral Fosmanogepix, a First-in-Class Antifungal Agent, in Healthy Volunteers. Antimicrobial Agents and Chemotherapy. 2023;67(4). doi:10.1128/aac.01623-22

BibTeX
@article{Hodges2023,
  author = {Hodges, Michael R and Ople, Eric and Wedel, Pamela and Shaw, Karen J and Jakate, Abhijeet and Kramer, William G and Marle, Sjoerd van and van Hoogdalem, Ewoud-Jan and Tawadrous, Margaret},
  title = {Safety and Pharmacokinetics of Intravenous and Oral Fosmanogepix, a First-in-Class Antifungal Agent, in Healthy Volunteers},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2023},
  volume = {67},
  number = {4},
  doi = {10.1128/aac.01623-22}
}
Kostenlos starten →